<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23931791</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0072-9752</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>115</Volume>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>Handbook of clinical neurology</Title>
          <ISOAbbreviation>Handb Clin Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Guillain-Barré syndrome.</ArticleTitle>
        <Pagination>
          <StartPage>383</StartPage>
          <EndPage>402</EndPage>
          <MedlinePgn>383-402</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/B978-0-444-52902-2.00021-7</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">B978-0-444-52902-2.00021-7</ELocationID>
        <Abstract>
          <AbstractText>The latest estimation for the frequency of Guillain-Barré syndrome (GBS) is 1.1 to 1.8 per 100000 persons per year. Guillain-Barré syndrome is today divided into two major subtypes: acute inflammatory demyelinating polyneuropathy (AIDP) and the axonal subtypes, acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN). The axonal forms of GBS are caused by certain autoimmune mechanisms, due to a molecular mimicry between antecedent bacterial infection (particularly Campylobacter jejuni) and human peripheral nerve gangliosides. Improvements in patient management in intensive care units has permitted a dramatic drop in mortality rates. Immunotherapy, including plasma exchange (PE) or intravenous immunoglobulin (IVIg), seems to shorten the time to recovery, but their effect remains limited. Further clinical investigations are needed to assess the effect of PE or IVIg on the GBS patients with mild affection, no response, or relapse.</AbstractText>
          <CopyrightInformation>Copyright © 2013 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fujimura</LastName>
            <ForeName>Harutoshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Toneyama National Hospital, Toneyama, Toyonaka, Japan. Electronic address: hfujim@toneyama.hosp.go.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Handb Clin Neurol</MedlineTA>
        <NlmUniqueID>0166161</NlmUniqueID>
        <ISSNLinking>0072-9752</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D020275" MajorTopicYN="N">Guillain-Barre Syndrome</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="Y">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009431" MajorTopicYN="N">Neural Conduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010525" MajorTopicYN="N">Peripheral Nerves</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Campylobacter jejuni</Keyword>
        <Keyword MajorTopicYN="N">Guillain–Barré syndrome</Keyword>
        <Keyword MajorTopicYN="N">acute inflammatory demyelinating polyneuropathy</Keyword>
        <Keyword MajorTopicYN="N">acute motor axonal neuropathy</Keyword>
        <Keyword MajorTopicYN="N">ganglioside</Keyword>
        <Keyword MajorTopicYN="N">intravenous immunoglobulin</Keyword>
        <Keyword MajorTopicYN="N">molecular mimicry</Keyword>
        <Keyword MajorTopicYN="N">plasma exchange</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23931791</ArticleId>
        <ArticleId IdType="doi">10.1016/B978-0-444-52902-2.00021-7</ArticleId>
        <ArticleId IdType="pii">B978-0-444-52902-2.00021-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
